ERNA - Latest News
Ernexa Therapeutics Inc. (ERNA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $3.4M. Beta to the broader market is 2.65.
The article list below shows the most recent ERNA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ERNA Headlines
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
globenewswire.com - Oct 12, 2026
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa's
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
globenewswire.com - Oct 6, 2026
Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be prese
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
globenewswire.com - Oct 1, 2026
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrat
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
globenewswire.com - Sep 30, 2026
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopa
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
globenewswire.com - Sep 29, 2026
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector
How News Affects ERNA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ERNA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ERNA news questions
- What is the latest ERNA news headline?
- The most recent ERNA headline (Oct 12, 2026) is "Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ERNA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ERNA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ERNA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.